

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l., (Holdings) Inc.

長 江 生 命 科 技 集 團 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

BUSINESS UPDATE ON HALNEURON[®] (TETRODOTOXIN FOR INJECTION)

CK Life Sciences Int'l., (Holdings) Inc. (the “Company”) announces that the U.S. Food and Drug Administration (the “FDA”) has granted to WEX Pharmaceuticals Inc., a late-stage drug development company wholly-owned by the Company, Fast Track designation for Halneuron[®] (Tetrodotoxin for Injection) for the treatment of chemotherapy-induced neuropathic pain (“CINP”).

The FDA’s Fast Track program aims to speed up the development and review of treatments for serious conditions and unmet medical needs, helping new medicines reach patients more quickly. Companies with Fast Track designation benefit from more frequent interactions with the FDA during clinical development and may qualify for accelerated approval or priority review if they meet the necessary criteria.

It should be noted that Halneuron[®] is only at the Phase 2B clinical trial stage for CINP and the data is subject to further review by the relevant regulatory authorities. There is accordingly no assurance of the outcome. Shareholders of the Company and potential investors are therefore advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
CK Life Sciences Int'l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 22 August 2024

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).